Impact of the GH-cortisol ratio on the age-dependent changes in body composition

Growth Hormone and IGF Research

Volumn 12, Issue 3, 2002, Pages 147-161

  Nass, R ^a   Thorner, M O ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aging; Body composition; Growth hormone; Hypercortisolism

Indexed keywords

GHRELIN; GLUCOCORTICOID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HYDROCORTISONE; SOMATOMEDIN C;

ADIPOCYTE; ADULT; AGED; AGING; BODY COMPOSITION; BODY FAT; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE ACTION; HORMONE DETERMINATION; HORMONE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEAN BODY WEIGHT; LIPID STORAGE; LIPOLYSIS; MALE; MUSCLE STRENGTH; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 0036592189     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(02)00022-9     Document Type: Review

References (251)

1. Novack L. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J Gerontol 1972; 27: 443-483.
2. Thompson JL, Butterfield GE, Marcus R, et al. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995; 80: 1845-1852.
3. Clasey JL, Weltman A, Patrie J, et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab 2001; 86: 3845-3852.
4. Shimokata H, Tobin J, Muller D, Elahi D, Coon P, Andres R. Studies in the distribution of body fat. I. Effects of age, sex, and obesity. J Gerontol 1989; 44: 67-73.
5. Enzi G, Gasparo M, Biondetti P, Fiore D, Semissa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr 1986; 44: 739-746.
6. Muenzer T, Harman S, Hees P, et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001; 86: 3604-610.
7. Forbes G, Reina J. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653-663.
8. Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc 1985; 33: 800-807.
9. Marcus R. Skeletal Aging-Understanding the functional and structural basis of osteoporosis. Trends Endocrinol Metab 1991; 2: 53-58.
10. Hannan M, Felson D, Anderson J. Bone mineral density in elderly men and women: results from the Framingham Osteoporosis Study. J Bone Miner Res 1992; 7: 547-553.
11. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972; 35: 665-670.
12. Zadik Z, Chalew SA, McCarter RJ Jr., Meistas M, Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985; 60: 513-516.
13. Rudman D, Feller A, Nagraj H, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
14. Salomon F, Cuneo R, Hesp R, Sonksen P. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803.
15. Holmes S, Economou G, Whitehouse R, Adams J, Shalet S. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 87: 669-674.
16. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993; 129: 201-206.
17. Wuester C, Slenczka E, Ziegler R. Erhohte Praevalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusatzlichen Wachstumshormonsubstitution?. Klin Wochenschr 1991; 69: 769-773.
18. Rosen T, Bosaeus I, Tolli J, Lindstedt G, Bengtsson B. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxford) 1993; 38: 63-71.
19. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309-317.
20. Snel YE, Brummer RJ, Doerga ME, et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 1995; 61: 1290-1294.
21. Snel YE, Doerga ME, Brummer RM, Zelissen PM, Koppeschaar HP. Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement. Arterioscler Thromb Vasc Biol 1995; 15: 1543-1548.
22. Stevens J. Obesity, fat patterning and cardiovascular risk. Adv Exp Med Biol 1995; 369: 21-27.
23. Ribeiro-Filho FF, Faria AN, Kohlmann O Jr., et al. Ultrasonography for the evaluation of visceral fat and cardiovascular risk. Hypertension 2001; 38: 713-717.
24. Kobayashi H, Nakamura T, Miyaoka K, et al. Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circulation J 2001; 65: 193-199.
25. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961-967.
26. Pascot A, Despres JP, Lemieux I, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000; 43: 1126-1135.
27. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000; 54(Suppl 3): S48-53.
28. Ghiron LJ, Thompson JL, Holloway L, et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995; 10: 1844-1852.
29. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124: 708-716.
30. Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994; 79: 1361-1366.
31. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997; 46: 89-96.
32. Frick K, Weltman JY, Wideman L, et al. Three months of recombinant human GHRH-1,44-amide administration in the older male enhances body composition and functional performance. In: Endocrine Society Meeting, Denver, 2001 (Abstract P2-286).
33. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001; 86: 1116-1125.
34. Deuschle M, Gotthardt U, Schweiger U, et al. With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. Life Sci 1997; 61: 2239-2246.
35. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA 2000; 284: 861-868.
36. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect Cushing's disease of the omentum?. Lancet 1997; 349: 1210-1213.
37. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the growth hormone research society workshop on adult growth hormone deficiency, J. Clin. Endocrinol. Metab. 1998; 83: 379-381.
38. Whitehead HM, Boreham C, McIlrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxford) 1992; 36: 45-52.
39. Binnerts A, Swart GR, Wilson JH, et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body com~osition. Clin Endocrinol (Oxford) 1992; 37: 79-87.
40. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997; 82: 82-88.
41. Cuneo RC, Salomon F, Wiles CM, Sonksen PH. Skeletal muscle performance in adults with growth hormone deficiency. Horm Res 1990; 33(Suppl 4): 55-60.
42. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288.
43. Bing-You RG, Denis MC, Rosen CJ. Low bone mineral density in adultswith previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 1993; 52: 183-187.
44. Black MM, Shuster S, Bottoms E. Skin collagen and thickness in acromegaly and hypopituitarism. Clin Endocrinol (Oxford) 1972; 1: 259-263.
45. Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221-1225.
46. Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995; 80: 552-557.
47. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991; 70: 695-700.
48. Rosen T, Johannson G, Hallgren P, Caidahl K, Bosaeus I, Bengtsson BA. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab 1994; 1: 55-66.
49. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxford) 1993; 39: 409-415.
50. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 883-890.
51. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: 2865-2873.
52. Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The effect of long term GH replacement on bone mineral density and metabolism in hypopituitary adults. Clin Endocrinol (Oxford) 2001; 54: 525-532.
53. O'Halloran D, Tsatsoulis A, Whitehouse R, Holmes S, Adams J, Shalet S. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993; 76: 1344-1348.
54. Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 2001; 86: 3079-3085.
55. Raben MS, Hollenberg H. Effect of growth hormone on plasma fatty acids. J Clin Invest 1959; 38: 484-488.
56. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol 2000; 25: 287-298.
57. Oberbauer AM, Stem JS, Johnson PR, et al. Body composition of inactivated growth hormone (oMt1a-oGH) transgenic mice: generation of an obese phenotype. Growth Dev Aging 1997; 61: 169-179.
58. Donahue LR, Beamer WG. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protem-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J Endocrinol 1993; 136: 91-104.
59. Furuhata Y, Kagaya R, Hirabayashi K, et al. Development of obesity in transgenic rats with low circulating growth hormone levels: involvement of leptin resistance. Eur J Endocrinol 2000; 143: 535-541.
60. Knapp JR, Chen WY, Turner ND, Byers FM, Kopchick JJ. Growth patterns and body composition of transgenic mice expressing mutated bovine somatotropin genes. J Anim Sci 1994; 72: 2812-2819.
61. Smith SR. The endocrinology of obesity. Obesity, Endocrinology and Metabolism Clinics of North America 1996; 25: 921-942.
62. Bell JP, Donald RA, Espiner EA. Pituitary response to insulin-induced hypoglycemia in obese subjects before and after fasting. J Clin Endocrinol Metab 1970; 31: 546-551.
63. Williams T, Berelowitz M, Joffe SN, et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med 1984; 311: 1403-1407.
64. Kopelman PG, Noonan K, Goulton R, Forrest AJ. Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity. Clin Endocrinol (Oxford) 1985; 23: 87-94.
65. Cordido F, Dieguez C, Casanueva FF. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. J Clin Endocrinol Metab 1990; 70: 1361-1370.
66. Kelijman M, Frohmnan LA. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects. J Clin Endocrinol Metab 1988; 66: 489-494.
67. Londono HJ, Gallagher TF, Bray GA. Effect of weight reduction, triiodothyronine, and diethylstilbestrol on growth hormone in obesity. Metabolism 1969; 18: 986-992.
68. Weltman A, Weltman JY, Hartman ML, et al. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab 1994; 78: 543-548.
69. Medeiros-Neto G, Lima N, Perozim L, Pedrinola F, Wajchenberg BL. The effect of hypocaloric diet with and without D-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity. Metabolism 1994; 43: 969-973.
70. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity [see comments] J Clin Endocrinol Metab 1993; 76: 819-823.
71. Andreotti AC, Lanzi R, Manzoni MF, Caumo A, Moreschi A, Pontiroli AE. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects. Metabolism 1994; 43: 1207-1213.
72. Casanueva FF, Villanueva L, Dieguez C, et al. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab 1987; 65: 634-642.
73. Lee EJ, Nam SY, Kim KR, et al. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects. J Clin Endocrinol Metab 1995; 80: 2495-2498.
74. Lee EJ, Kim KR, Lee HC, et al. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism. Metabolism 1995; 44: 1509-1512.
75. Nam SY, Lee, Kim KR, et al. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity. Metabolism 1996; 45: 594-597.
76. Rasmussen MH, Frystyk J, Andersen T, Breum L, Christiansen JS, Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 1994; 43: 315-319.
77. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 1997; 272: E1108-1116.
78. Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen J, Jorgensen JO. Growth hormone treatment of obese women body for 5 wk: effect on composition and adipose tissue LPL activity. Am J Physiol 1994; 266: E211-216.
79. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991; 40: 1323-1326.
80. Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. British Medical Journal Clinical Research Ed 1985; 290: 1692-1694.
81. DeNino WF, Tchernof A, Dionne IJ, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 2001; 24: 925-932.
82. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed tomography. J Gerontol 1983; 38: 673-677.
83. Schwartz RS, Shuman WP, Bradbury VL, Cain KC, Fellingham GW, Beard JC, Kahn SE, Stratton JR, Cerqueira MD, Abrass IB. Body fat distribution in healthy young and older men. J Gerontol 1990; 45(6): 181-185.
84. Stiegler C, Leb G. One year of replacement therapy in adults with growth hormone deficiency. Endocrinol Metab 1994; 1: 37-42.
85. de Boer H, Blok GJ, van Lingen A, Teule GJ, Lips P, van der Veen EA. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994; 9: 1319-1326.
86. Gamero P, Sornay-Rendu E, Delmas PD. Low serum IGF-I and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000; 355: 898-899.
87. Marcus R, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metabol 1990; 70: 519-527.
88. Taaffe DR, Thompson JL, Butterfield GE, Hoffman AR, Marcus R. Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program. Horm Metab Res 2001; 33: 156-162.
89. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981; 67: 1361-1369.
90. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64: 51-58.
91. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991; 7: 1081-1088.
92. Vermeulen A. Nyctohemoral growth hormone profiles in young and aged men: correlations with somatomedin-C levels. J Clin Endocrinol Metab 1987; 64: 884-888.
93. Carlson HE, Gillin JC, Gordon P, Snyder F. Absence of sleep-related growth hormone peaks in aged normal subjects and in acromegaly. J Clin Endocrinol Metab 1972; 34: 1102-1105.
94. Prinz PN, Weitzman ED, Cunningham GR, Karacan I. Plasma growth hormone secretion during nocturnal sleep in course of aging. J Gerontol 1983; 38: 519-524.
95. Kern W, Dodt C, Born J, Fehm HL. Changes in cortisol and growth hormone secretion during nocturnal sleep in the course of aging. J Gerontol Series A-Biol Sci Med Sci 1996; 51: M3-9.
96. Orth D, Kovacs W, DeBold C. The adrenal cortex. In: Wilson JD, Foster DW (eds). Williams Textbook of Endocrinology, 9th ed. Philadelphia: W.B. Saunders; 1998: pp. 517-665.
97. Lonn L, Kvist H, Grangard U, Bengtsson BA, Sjostrom L. CT-determined body composition changes with recombinant human growth hormone treatment to adults with growth hormone deficiency. Basic Life Sci 1993; 60: 229-231.
98. Yanovski J, Cutler G. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am 1994; 23: 487-509.
99. Wajchenberg BL, Bosco A, Marone MM, et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995; 80: 2791-2794.
100. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome [see comments]. J Clin Endocrinol Metab 1995; 80: 2859-2865.
101. Lufkin EG, Wahner HW, Bergstralh EJ. Reversibility of steroid-induced osteoporosis. Am J Med 1988; 85: 887-888.
102. Lamberts SW, Birkenhager JC. Body composition in Cushing's disease. J Clin Endocrinol Metab 1976; 42: 864-868.
103. Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331: 629-636.
104. Meunier PJ, Dempster DW, Edouard C, Chapuy MC, Arlot M, Charhon S. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 1984; 171: 191-200.
105. Ross EJ, Linch DC. Cushing's syndrome - killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646-649.
106. Kemink SA, Frijns JT, Hermus AR, Pieters GF, Smals AG, van Marken Lichtenbelt WD. Body composition determined by six different methods in women bilaterally adrenalectomized for treatment of Cushing's disease. J Clin Endocrinol Metab 1999; 84:3991-3999.
107. Mayo-Smith W, Hayes C, Biller B. Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa and patients with Cushing's syndrome. Radiology 1989; 170: 515-518.
108. Loenn L, Kvist H, Ernest I, Sjostrom L. Changes in body composition and adipose tissue distribution after treatment of women with Cushing's syndrome. Metabolism 1994; 43: 1517-1522.
109. Marin P, Darin N, Amemyia T, Andersson B, Jern S, Bjoerntrop P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992; 41: 882-886.
110. Pasquali R, Cantobelli S, Casimirri F, et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993; 77: 341-346.
111. Moyer AE, Rodin J, Grilo CH, Cummings N, Larsson LM, Rebuffe-Scrive M. Stress-induced cortisol resonse and fat distribution in women. Obes Res 1994; 2: 255-262.
112. Streeten DH. Is hypothalamic-pituitary-adrenal hyperactivity important in the pathogenesis of excessive abdominal fat distribution? [letter; comment] J Clin Endocrinol Metab 1993; 77:339-340.
113. Dallman MF. Stress update. Adaptation of the hypothalamic-pituitary-adrenal axis to chronic stress. Trends Endocrinol Metab 1993; 4: 62-69.
114. Jessop DS, Dallman MF, Flemming D, Lightman SL. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001; 86: 4109-4114.
115. Dobson MG, Redfern CP, Unwin N, WeaverJU. The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus.J Clin Endocrinol Metab 2001; 86: 2270-2274.
116. Rosmond R, Chagnon YC, Holm G, et al. A glucocorticoid. receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res 2000; 8: 211-218.
117. Weaver JU, Taylor NF, Monson JP, Wood PJ, Kelly WF. Sexual dimorphism in 11β-hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity; a study in hypopituitary subjects [see comments] Clin Endocrinol (Oxford) 1998; 49: 13-20.
118. Stewart PM. 'The fat lady sings', but what is she telling us? [letter; comment] Clin Endocrinol (Oxford) 1998; 49: 9-10.
119. Stewart PM. Cortisol, hypertension and obesity: the role of 11β-hydroxysteroid dehydrogenase. J R Coll Physicians Lond 1998; 32: 154-159.
120. Livingstone DEW, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese zucker rats. Endocrinology 2000; 141(2): 560-563.
121. Peeke P, Oldfield E, Alexander H, et al. Glucocorticoid receptor expression in patients with Cushing syndrome. In: North American Society for the Study of Obesity, Minneapolis, MI, 1993 (Abstract).
122. Rebuffe-Scrive M, Andersson B, Olbe L, Bjoerntorp P. Metabolism of adipose tissue in intraabdominal depots in severly obese men and women. Metabolism 1990; 39: 1021-1025.
123. Ottosson M, Marin P, Karason K, Elander A, Bjorntorp P. Blockade of the glucocorticoid receptor with RU 486: effects in vitro and in vivo on human adipose tissue lipoprotein lipase activity. Obes Res 1995; 3: 233-240.
124. Ottosson M, Vikman-Adolfsson K, Enerbak S, Elander A, Bjoerntrop P, Eden S. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1995; 80: 936-941.
125. Hughes NR, Lissett CA, Shalet SM. Growth hormone status following treatment for Cushing's syndrome. Clin Endocrinol (Oxford) 1999; 51: 61-66.
126. Pavlov EP, Harman SM, Chrousos GP, Loriaux DL, Blackman MR. Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986; 62: 767-772.
127. Zumoff B, Fukushima DK, Weitzman ED, Kream J, Hellman L. The sex difference in plasma cortisol concentration in man. J Clin Endocrinol Metab 1974; 39: 805-808.
128. Friedman M, Green MF, Sharland DE. Assessment of hypothalamic-pituitary-adrenal function in the geriatric age group. J Gerontol 1969; 24: 292-297.
129. Green MF, Friedman M. Hypothalamic-pituitary-adrenal function in the elderly. Gerontol Clin 1968; 10: 334-339.
130. Van Coevorden A, Mockel J, Laurent E, et al. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 199 1; 260: E651-661.
131. Yau JL, Noble J, Kenyon CJ, et al. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Nat Acad Sci USA 2001; 98: 4716-4721.
132. Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NP, Meaney MJ. Basal cortisol levels and cognitive deficits in human aging. J Neurosci 1994; 14: 2893-2903.
133. Lupien SJ, de Leon M, de Santi S, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits [see comments]. Nature Neurosci 1998; 1: 69-73.
134. Seckl JR, Olsson T. Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect?. J Endocrinol 1995; 145: 201-211.
135. Veldhuis JD. Altered pulsatile and coordinate secretion of pituitary hormones in aging: evidence of feedback disruption. Aging (Milano) 1997; 9: 19-20.
136. Sapolsky RM, Krey LC, McEwen BS. The adrenocortical axis in the aged rat: impaired sensitivity to both fast and delayed feedback inhibition. Neurobiol Aging 1986; 7: 331-335.
137. Wilkinson CW, Petrie EC, Murray SR, Colasurdo EA, Raskind MA, Peskind ER. Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. J Clin Endocrinol Metab 2001; 86: 545-550.
138. Cavagnini F, Croci M, Putignano, P, Petroni ML, Invitti C. Glucocorticoids and neuroendocrine function. Int J Obes Relat Metab Disord 2000; 24(Suppl 2): S77-S79.
139. De Kloet E. Steroids, stability and stress. Front Neuroendocrinol 1995; 16: 416-425.
140. Ratka A, Sutanto W, Bloemers M, de Kloet ER. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 1989; 50: 117-123.
141. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticold receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-275.
142. De Kloet R, Wallach G, McEwen BS. Differences in corticosterone and dexamethasone binding to rat brain and pituitary. Endocrinology 1975; 96: 598-609.
143. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895.
144. Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985; 117: 2505-2511.
145. Reul JM, de Kloet ER, van Sluijs FJ, Rijnberk A, Rothuizen J. Binding characteristics of mineralocorticoid and glucocorticoid receptors in dog brain and pituitary. Endocrinology 1990; 127: 907-915.
146. Sutanto W, De Kloet ER. Species-specificity of corticosteroid receptors in hamster and rat brains. Endocrinology 1987; 121: 1405-1411.
147. Landfield PW, Waymire JC, Lynch G. Hippocampal aging and adrenocorticoids: quantitative correlations. Science 1978; 202: 1098-1102.
148. Packan DR, Sapolsky RM. Glucocorticoid endangerment of the hippocampus: tissue steroid and receptor specificity. Neuroendocrinology 1990; 51: 613-618.
149. Herman JP, Larson BR, Speert DB, Seasholtz AF. Hypothalamo-pituitary-adrenocortical dysregulation in aging F344/Brown-Norway F1 hybrid rats. Neurobiol Aging 2001; 22: 323-332.
150. Waltman C, Blackman MR, Chrousos GP, Riemann C, Harman SM. Spontaneous and glucocorticoid-inhibited adrenocorticotropic hormone and cortisol secretion are similar in healthy young and old men. J Clin Endocrinol Metab 1991; 73: 495-502.
151. Seeman TE, Singer B, Wilkinson CW, McEwen B. Gender differences in age-related changes in HPA axis reactivity. Psychoneuroendocrinology 2001; 26: 225-240.
152. Seeman TE, Robbins RJ. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocr Rev 1994; 15: 233-260.
153. Giordano R, Di Vito L, Lanfranco F, et al. Elderly subjects show severe impairment of dehydroepiandrosterone sulphate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH(1-24). Clin Endocrinol (Oxford) 2001; 55: 259-265.
154. Blichert-Toft M. Secretion of Corticotrophin and Somatototrophin by the Senescent Aderrohypophysis in man. Acta Endocrinol (Copenh) Supplementum 1975; 78: 15-154.
155. Blichert-Toft M, Hippe E, Kjensen HK. Adrenal cortical function as reflected by the plasma hydrocortisone and urinary 17-ketogenic steroids in relation to surgery in elderly patients. Acta Chir Scand 1967; 133: 591-599.
156. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984; 5: 25-44.
157. Rosenbaum AH, Schatzberg AF, MacLaughlin RA, et al. The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. Am J Psychiatry 1984; 141: 1550-1555.
158. Asnis GM, Sachar EJ, Halbreich U, Nathan RS, Novacenko H, Ostrow LC. Cortisol secretion in relation to age in major depression. Psychosom Med 1981; 43: 235-242.
159. Davis KL, Davis BM, Mathe AA, et al. Age and the dexamethasone suppression test in depression. Am J Psychiatry 1984; 141: 872-874.
160. Lewis DA, Pfohl B, Schlechte J, Coryell W. influence of age on the cortisol response to dexamethasone. Psychiatry Res 1984; 13: 213-220.
161. Fogel BS, Satel SL, Levy S. Occurrence of high concentrations of postdexamethasone cortisol in elderly psychiatric inpatients. Psychiatry Res 1985; 15: 85-90.
162. Greenwald BS, Mathe AA, Mohs RC, Levy MI, Johns CA, Davis KL. Cortisol and Alzheimer's disease, II: dexamethasone suppression, dementia severity, and affective symptoms. Am J Psychiatry 1986; 143: 442-446.
163. Anton RF. Urinary free cortisol in psychotic depression. Biol Psychiatry 1987; 22: 24-34.
164. Tourigny-Rivard ME, Raskind M, Rivard D. The dexamethasone suppression test in an elderly population. Biol Psychiatry 1981; 16: 1177-1184.
165. Huizenga NA, Koper JW, de Lange P, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 1998; 83: 47-54.
166. Ohashi M, Fujio N, Kato K, Nawata H, Ibayashi H. Aging is without effect on the pituitary-adrenal axis in men. Gerontology 1986; 32: 335-339.
167. Greenspan SL, Rowe JW, Maitland LA, McAloon-Dyke M, Elahi D. The pituitary-adrenal glucocorticoid response is altered by gender and disease. J Gerontol 1993; 48: M72-7.
168. Rosmond R, Chagnon M, Bouchard C, Bjorntorp P. A polymorphism in the regulatory region of the corticotropin-releasing hormone gene in relation to cortisol secretion, obesity, and gene-gene interaction. Metabolism 2001; 50: 1059-1062.
169. Fife SK, Brogan RS, Giustina A, Wehrenberg WB. immunocytochemical and molecular analysis of the effects of glucocorticoid-treatment on the hypothalamic-somatotropic axis in the rat. Neuroendocrinology 1996; 64: 131-138.
170. Lam KS, Srivastava G. Gene expression of hypothalamic somatostatin and growth hormone-releasing hormone in dexamethasone-treated rats. Neuroendocrinology 1997; 66: 2-8.
171. Senaris RM, Lago F, Coya R, Pineda J, Dieguez C. Regulation of hypothalamic somatostatin, growth-hormone-releasing hormone, and growth hormone receptor messenger ribonucleic acid by glucocorticoids. Endocrinology 1996; 137: 5236-5241.
172. Nakagawa K, Ishizuka T, Obara T, Matsubara M, Akikawa K. Dichotomic action of glucocorticoids on growth hormone secretion. Acta Endocrinol (Copenh) 1987; 116: 165-171.
173. Fernandez-Vaquez G, Cacicedo L, Lorenzo MG, Tolon R, Lopez J, Sanchez-Franco F. Corticosterone modulates growth hormone-releasing factor and somatostatin in fetal rat hypothalamic cultures. Neuroendocrinology 1995; 61: 31-35.
174. Kohler PO, Bridson WE, Rayford PL. Cortisol stimulation of growth hormone production by monkey adenohypophysis in tissue culture. Biophys Res Commun 1968; 33: 834-840.
175. Vale W, Vaughan J, Yamamoto G, Spiess J, Rivier J. Effects of synthetic human pancreatic (tumor) GH releasing factor and somatostatin, triiodothyronine and dexamethasone on GH secretion in vitro. Endocrinology 1983; 112: 1553-1555.
176. Bancroft FC, Levine L, Tashjian AH. Control of growth hormone production by a clonal strain of rat pituitary cells: stimulation by hydrocortisone. J Cell Biol 1969; 43: 432-441.
177. Casanueva FF, Burguera B, Tome MA, et al. Depending on the time of administration, dexamethasone potentiates or blocks growth honnone-releasing hormone-induced growth hormone release in man. Neuroendocrinology 1988; 47: 46-49.
178. Pantelakis SN, Sinaniotis CA, Sbirakis S, Ikkos D, Doxiadis SA. Night and day growth hormone levels during treatment with corticosteroids and corticotrophin. Arch Dis Child 1972; 47: 605-608.
179. Magiakou M, Mastorakos G, Gomez M, Rose S, Chrousos G. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994; 78: 131-137.
180. Allen D, Julius J, Breen T, Attie K. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998; 83: 2824-2829.
181. Demura R, Demura H, Nunokawa T, Baba H, Imura K. Responses of plasma ACTH, GH, LH, and 11-hydroxycorticosteroids to various stimuli in patients with Cushing's syndrome. J Clin Endocrinol Metab 1972; 34: 852-859.
182. Kaufmann S, Jones KL, Wehrenberg WB, Culler FL. Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab 1988; 67: 1258-1261.
183. Krieger DT, Glick SM. Sleep EEG stages and plasma growth hormone concentration in states of endogenous hypercortisolemia or ACTH elevation. J Clin Endocrinol Metabol 1974; 39: 986-1000.
184. Smals AE, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW. Human pancreatic growth hormone releasing hormone fails to stimulate human growth hormone both in Cushing's disease and in Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxford) 1986; 24: 401-407.
185. del Balzo P, Salvatori R, Cappa M, Gertner JM. Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition. Clin Endocrinol (Oxford) 1990; 33: 605-612.
186. Charmandari E, Pincus SM, Matthews DR, Dennison E, Fall CH, Hindmarsh PC. joint growth hormone and cortisol spontaneous secretion is more asynchronous in older females than in their male counterparts. J Clin Endocrinol Metab 2001; 86:3393-3399.
187. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-797.
188. Bjoerntorp P. The regulation of adipose tissue distribution in humans. Int J Obes 1996; 20: 291-302.
189. Wolf G. The molecular mechanism of the stimulation of adipocyte differentiation by a glucocorticoid. Nutr Rev 1999; 57:324-326.
190. Hansen L, Madsen B, Teisner B, Nielsen J, Billestrup N. Characterization of the inhibitory effect of growth hormone on primary preadipocyte differentiation. Mol Endocrinol 1998; 12: 1140-1149.
191. Ortoft G, Andreassen T, Oxlund H. Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia. J Bone Miner Res 1999; 14: 710-721.
192. Bennet WM, Haymond MW. Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment. Clin Endocrinol (Oxford) 1992; 36: 161-164.
193. Kovacs G, Fine RN, Worgall S, et al. Growth hormone prevents steroid-induced growth depression in health and uremia. Kidney Int 1991; 40: 1032-1040.
194. Woodhouse L, Asa S, Thomas S, Ezzat S. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-defcient adults. J Clin Endocrinol Metab 1999; 84: 4570-4577.
195. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjoerntrop P. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1988; 67: 1122-1128.
196. Kimura K, Kanda F, Okuda S, Chihara. K. Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells. Neurosci Lett 2001; 302: 154-156.
197. Simmons P, Miles J, Gerich J, Hammond M. Increased proteolysis: an effect of increases in plasma cortisol within the physiologic range. J Clin Invest 1984; 73: 412-420.
198. Beauftere B, Horber F, Schwenk W, et al. Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol 1989; 257: E712-721.
199. Horber FF, Scheidegger JR, Grunig BE, Frey FJ. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985; 61: 83-88.
200. Horber FF, Scheidegger JR, Grunig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 1985; 15: 302-307.
201. Tischler ME. Hormonal regulation of protein degradation in skeletal and cardiac muscle. Life Sci 1981; 28: 2569-2576.
202. Darmaun D, Matthews DE, Bier DM. Physiological hypercortisolemia increases proteolysis, glutamme, and alanine production. Am J Physiol 1988; 255: E366-373.
203. Louard RJ, Bhushan R, Gelfand RA, Barrett EJ, Sherwin RS. Glucocorticoids antagonize insulin's antiproteolytic action on skeletal muscle in humans. J Clin Endocrinol Metab 1994; 79: 278-284.
204. Liu Z, Jahn LA, Long W, Fryburg DA, Wei L, Barrett EJ. Branched chain amino acids activate messenger ribonucleic acid translation regulatory proteins in human skeletal muscle, and glucocorticoids blunt this action. J Clin Endocrinol Metab 2001; 86:2136-2143.
205. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998; 83: 403-409.
206. Horber F, Haymond M. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86: 265-272.
207. Fryburg DA, Gelfand RA, Barrett EJ. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol 1991; 260: E499-504.
208. Trainer P, Drake W, Perry L, Taylor N, Besser G, Monson J. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 2001; 86: 2989-2992.
209. Seckl JR, Walker BR. Minireview: 11β-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376.
210. Diederich S, Quinkler M, Burkhardt P, Grossmann C, Bahr V, Oelkers W. 11Beta-hydroxysteroid-dehydrogenase isoforms: tissue distribution and implications for clinical medicine. Eur J Clin Invest 2000; 30(Suppl 3): 21-27.
211. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenase. Best Practice & Research Clinical Endocrinology & Metabolism 2001; 15: 61-78.
212. Shimojo M, Condon J, Whorwood CB, Stewart PM. Adrenal 11β-hydroxysteroid dehydrogenase. Endocr Res 1996; 22: 771-780.
213. Li A, Tedde R, Krozowski ZS, et al. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Am J Hum Genet 1998; 63: 370-379.
214. Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991; 266: 16653-16658.
215. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochernical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998; 83: 1325-1335.
216. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188-3196.
217. Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE. 11Beta-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 1998; 64: 251-260.
218. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294:2166-2170.
219. Gelding S, Taylor N, Wood P, et al. The effect of growth hormone replacement therapy on the cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11(β)-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxford) 1998; 48: 153-162.
220. Toogood AA, Taylor NF, Shalet SM, Monson JP. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 2000; 85: 1727-1730.
221. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001; 12: 118-122.
222. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
223. Hosada H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279: 909-913.
224. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-977.
225. Pong SS, Chaung LY, Dean DC, et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996; 10: 57-61.
226. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000; 85: 4908-4911.
227. Imbimbo BP, Mant T, Edwards M, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol 1994; 46: 421-425.
228. Chapman IM, Hartman ML, Pezzoli SS, Thorner MO. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults -- a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2874-2880.
229. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993; 76: 1202-1208.
230. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-1545.
231. Thorner MO, Vance ML, Rogol AD, et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as potential therapeutic modalities. Acta Paediatrica Suppl 1990; 367: 29-32.
232. Ghigo E, Arvat E, Muccioli G, et al. Growth hormone-releasing peptides. Eur J Endocrinol 1997; 136: 445-460.
233. Korbonits M, Kaltsas G, Perry LA, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin [see comments]. J Clin Endocrinol Metab 1999; 84: 2489-2495.
234. Loche S, Colao A, Cappa M, et al. Adrenocorticotropin-and cortisol-releasing effect of hexarelin, a synthetic growth-hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997; 82: 861-864.
235. Thomas GB, Fairhall KM, Robinson IC. Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 1997; 138: 1585-1591.
236. Clark RG, Thomas GB, Mortensen DL, et al. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 1997; 138: 4316-4323.
237. Smith RG, Pong SS, Hickey SS, et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Horm Res 1996; 51: 261-285.
238. Skinner MM, Nass R, Lopes B, et al. Growth hormone secretagogue receptor expression in human pituitary tumors. J Clin Endocrinol Metab 1998; 83: 4314-4320.
239. Adams EF, Huang B, Buchfelder M, et al. Presence of growth hormone secretagogue receptor messenger ribonucleic acid in human pituitary tumors and rat GH3 cells. J Clin Endocrinol Metab 1998; 83: 638-642.
240. Korbonits M, Jacobs RA, Aylwin SJ, et al. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J Clin Endocrinol Metab 1998; 83: 3624-3630.
241. Gertz BJ, Sciberras DG, Yogendran L, et al. L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994; 79: 745-749.
242. Torsello A, Luoni M, Schweiger F, et al. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur J Pharmacol 1998; 360: 123-129.
243. Toth DW, Hellman PH, Gordon DA, et al. Evidence that the orexigenic effect of ghrelin is mediated by a distinct GHS-R subtype. In: Endocrine Society Meeting, Denver, 2001, P1-90.
244. Thomas GB, Bennett PA, Carmignac DF, Robinson IC. Glucocorticoid regulation of growth hormone (GH) secretagogue-induced growth responses and GH secretagogue receptor expression in the rat. Growth Hormone & Igf Research 2000; 10: 45-52.
245. Kaji H, Kishimoto M, Kirimura T, et al. Hormonal regulation of the human ghrelin receptor gene transcription. Biochem Biophys Res Commun 2001; 284: 660-666.
246. Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM. Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 2001; 142: 2649-2659.
247. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120: 337-345.
248. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nature Reviews Neurosci 2001; 2: 551-560.
249. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
250. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325-4328.
251. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227-232.